Background: Alzheimer’s disease (AD) is a neurodegenerative disease with
well-characterized pathological features. Yet the underlying mechanisms have not been
resolved and an effective therapeutic approach is lacking. Cerebral hypoxia is considered
a risk factor of AD.
Objective: We tested whether oxygen supplementation can relieve AD symptoms
and how it affects the expression levels of proteins in the lens.
Methods: Triple transgenic AD model (3xTg-AD) mice were divided into oxygen
treated (OT) and control (Ctrl) groups. Their cognitive performances were tested in a
Morris water maze (MWM) paradigm. Then, their eye lens tissues were subjected to
quantitative proteomics analysis by the iTRAQ (isobaric tags for relative and absolute
quantification) method. The up- and downregulated proteins were classified according to a
Gene Ontology (GO) database in PANTHER. Behavioral and proteomic data were compared
between the groups.
Results: Mice in the OT group had better learning and memorizing performance
compared with the Ctrl group in MWM test. Lenses from the OT group had 205 differentially
regulated proteins, relative to lenses from the Ctrl group, including proteins that are
involved in the clearance of amyloid β-protein.
Conclusion: The results of this study indicate that oxygen treatment can
improve cognitive function in AD model mice and alters protein expression in a manner
consistent with improved redox regulation.
SwomleyAM, ButterfieldDA
(2015) Oxidative stress in Alzheimer disease and mild
cognitive impairment: Evidence from human data provided by redox
proteomics. Arch Toxicol89, 1669–1680.
7.
WatsonJD
(2014) Type 2 diabetes as a redox disease.
Lancet383, 841–843.
ThakurN, BlancPD, JulianLJ, YelinEH, KatzPP,
SidneyS, IribarrenC, EisnerMD
(2010) COPD and cognitive impairment: The role of hypoxemia
and oxygen therapy. Int J Chron Obstruct Pulmon Dis5, 263–269.
10.
BrownWR, ThoreCR
(2011) Review: Cerebral microvascular pathology in ageing
and neurodegeneration. Neuropathol Appl Neurobiol37, 56–74.
11.
YagerJY, WrightS, ArmstrongEA, JahrausCM, SaucierDM
(2006) The influence of aging on recovery following ischemic
brain damage. Behav Brain Res173, 171–180.
12.
ChangLY, LoweJ,
ArdilesA, LimJ,
GreyAC, RobertsonK, Danesh-MeyerH, PalaciosAG, AcostaML
(2014) Alzheimer’s disease in the human eye. Clinical tests
that identify ocular and visual information processing deficit as
biomarkers. Alzheimers Dement10, 251–261.
13.
ValentiDA
(2010) Alzheimer’s disease: Visual system
review. Optometry81, 12–21.
SongF, PoljakA, KochanNA, RafteryM, BrodatyH, SmytheGA, SachdevPS
(2014) Plasma protein profiling of mild cognitive impairment
and Alzheimer’s disease using iTRAQ quantitative proteomics.
Proteome Sci12, 13.
16.
WuWW, WangG,
BaekSJ, ShenRF
(2006) Comparative study of three proteomic quantitative
methods, DIGE, cICAT, and iTRAQ, using 2D Gel- or LC-MALDI TOF/TOF.
J Proteome Res5, 651–658.
17.
MiH, MuruganujanA, ThomasPD
(2013) PANTHER in 2013: Modeling the evolution of gene
function, and other gene attributes, in the context of phylogenetic
trees. Nucleic Acids Res41, D377–D386.
18.
RiddleDR, SonntagWE, LichtenwalnerRJ
(2003) Microvascular plasticity in aging.
Ageing Res Rev2, 149–168.
19.
ShaoWH, LiC,
ChenL, QiuX,
ZhangW, HuangCX, XiaL,
KongJM, TangY
(2010) Stereological investigation of age-related changes of
the capillaries in white matter. Anat Rec (Hoboken)293, 1400–1407.
20.
PfisterRH, SollRF
(2010) Hypothermia for the treatment of infants with
hypoxic-ischemic encephalopathy. J Perinatol30(Suppl),
82–87.
21.
DesmondDW, MoroneyJT, SanoM,
SternY, MerinoJG
(2002) Incidence of dementia after ischemic stroke: Results of
a longitudinal study * Editorial Comment. Stroke33, 2254–2262.
22.
PlutaR, KockiJ,
Ułamek-KoziołM,
PetniakA, Gil-KulikP, JanuszewskiS, BoguckiJ, JabłońskiM, BrzozowskaJ, Furmaga-JabłońskaW,
Bogucka-KockaA,
CzuczwarSJ
(2016) Discrepancy in expression of β-secretase and
amyloid-β medial temporal lobe cortex following transient global brain
ischemia. J Alzheimers Disdoi: 10.3233/JAD-151102.
23.
HoveidaR, AlaeiH,
OryanS, ParivarK, ReisiP
(2011) Treadmill running improves spatial memory in an
animal model of Alzheimer’s disease. Behav Brain Res216, 270–274.
24.
GoldsteinLE, MuffatJA, ChernyRA, MoirRD,
EricssonMH, HuangX,
MavrosC, CocciaJA, FagetKY, FitchKA, MastersCL, TanziRE, ChylackLT, BushAI
(2003) Cytosolic β-amyloid deposition and supranuclear
cataracts in lenses from people with Alzheimer’s disease.
Lancet361, 1258–1265.
25.
FrederiksePH,
GarlandD, ZiglerSJr,
PiatigorskyJ
(1996) Oxidative stress increases production of beta-amyloid
precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic
effects on lens epithelial cells. J Biol Chem271, 10169–10174.
OddoS, CaccamoA, ShepherdJD, MurphyMP, GoldeTE, KayedR,
MetherateR, MattsonMP, AkbariY, LaFerlaFM
(2003) Triple-transgenic model of Alzheimer’s disease with
plaques and tangles. Neuron39, 409–421.
28.
TannenbergRK,
ScottHL, TannenbergAE, DoddPR
(2006) Selective loss of synaptic proteins in Alzheimer’s
disease: Evidence for an increased severity with APOE varepsilon4.
Neurochem Int49, 631–639.
29.
DrewCJ, KydRJ,
MortonAJ
(2007) Complexin 1 knockout mice exhibit marked deficits in
social behaviours but appear to be cognitively normal. Hum Mol
Genet16, 2288–2305.
30.
YangL, ZhangY,
WangS, ZhangW,
ShiR (2014)
Decreased liver peroxisomal beta-oxidation accompanied by changes in
brain fatty acid composition in aged rats. Neurol Sci35, 289–293.
31.
BaarineM, AndreolettiP, AthiasA, NuryT,
ZarroukA, RagotK,
VejuxA, RiedingerJM, KattanZ, BessedeG, TrompierD, SavaryS, Cherkaoui-MalkiM,
LizardG (2012)
Evidence of oxidative stress in very long chain fatty acid–treated
oligodendrocytes and potentialization of ROS production using RNA interference-directed
knockdown of ABCD1 and ACOX1 peroxisomal proteins.
Neuroscience213, 1–18.
32.
MosserS, AlattiaJR, DimitrovM, MatzA,
PascualJ, SchneiderBL, FraeringPC
(2015) The adipocyte differentiation protein APMAP is an
endogenous suppressor of Abeta production in the brain. Hum Mol
Genet24, 371–382.
33.
FeherA, JuhaszA, LaszloA, PakaskiM, KalmanJ, JankaZ
(2013) Association between the ABCG2 C421A polymorphism and
Alzheimer’s disease. Neurosci Lett550, 51–54.
34.
Vidal-DonetJM,
Carcel-TrullolsJ,
CasanovaB, AguadoC, KnechtE
(2013) Alterations in ROS activity and lysosomal pH account
for distinct patterns of macroautophagy in LINCL and JNCL fibroblasts.
PLoS One8, e55526.
35.
SultanaR, PerluigiM, ButterfieldDA
(2009) Oxidatively modified proteins in Alzheimer’s disease
(AD), mild cognitive impairment and animal models of AD: Role of Abeta in
pathogenesis. Acta Neuropathol118, 131–150.
36.
MusunuriS, KultimaK, RichardBC, IngelssonM, LannfeltL, BergquistJ, ShevchenkoG
(2015) Micellar extraction possesses a new advantage for the
analysis of Alzheimer’s disease brain proteome. Anal Bioanal
Chem407, 1041–1057.
37.
ChoyRW, ChengZ,
SchekmanR
(2012) Amyloid precursor protein (APP) traffics from the
cell surface via endosomes for amyloid beta (Abeta) production in the trans-Golgi
network. Proc Natl Acad Sci U S A109, E2077–E2082.
38.
YunHM, JinP,
HanJY, LeeMS,
HanSB, OhKW,
HongSH, JungEY,
HongJT (2013)
Acceleration of the development of Alzheimer’s disease in amyloid
beta-infused peroxiredoxin 6 overexpression transgenic mice. Mol
Neurobiol48, 941–951.
39.
AnderssonU, TraceyKJ
(2011) HMGB1 is a therapeutic target for sterile inflammation
and infection. Annu Rev Immunol29, 139–162.
40.
ZanigniS, TerlizziR, TononC,
TestaC, MannersDN, CapellariS, GallassiR, PodaR,
GramegnaLL, Calandra-BuonauraG,
SambatiL, CortelliP, LodiR
(2015) Brain magnetic resonance metabolic and
microstructural changes in adult-onset autosomal dominant
leukodystrophy. Brain Res Bull117, 24–31.
41.
Di
PaolaM, SpallettaG, CaltagironeC
(2010) In vivo structural neuroanatomy of
corpus callosum in Alzheimer’s disease and mild cognitive impairment using different MRI
techniques: A review. J Alzheimers Dis20, 67–95.
42.
ZahidS, KhanR,
OellerichM, AhmedN,
AsifAR (2014)
Differential S-nitrosylation of proteins in Alzheimer’s
disease. Neuroscience256, 126–136.
43.
NakamuraT, TuS,
AkhtarMW, SunicoCR, OkamotoS, LiptonSA
(2013) Aberrant protein s-nitrosylation in neurodegenerative
diseases. Neuron78, 596–614.
44.
TortaF, UsuelliV, MalgaroliA, BachiA
(2008) Proteomic analysis of protein
S-nitrosylation. Proteomics8, 4484–4494.
45.
RiedererIM, SchiffrinM, KovariE, BourasC, RiedererBM
(2009) Ubiquitination and cysteine nitrosylation during
aging and Alzheimer’s disease. Brain Res Bull80, 233–241.
